| 12/31/2021 | ADUHELM™ (aducanumab-avwa) injection for Commercial Members (Updated January 1, 2022) | The purpose of this communication is to provide notification of the Company's position for ADUHELM™ (aducanumab-avwa) injection for all Commercial Products effective as of June 7, 2021.
| 0 | | ADUHELM™ (aducanumab-avwa) injection for Commercial Members (Updated January 1, 2022) | a9ee4734-cb58-454d-99d3-ec39e3d68714 |
| 12/31/2021 | Coverage of Speech Therapy Services Performed Through Telemedicine for Independence Commercial Members (Updated January 1, 2022) | The purpose of this communication is to provide notice regarding coverage for speech therapy services performed through telemedicine for our Independence Commercial members during the coronavirus disease 2019 public health emergency. | 0.1 | | Coverage of Speech Therapy Services Performed Through Telemedicine for Independence Commercial Members (Updated January 1, 2022) | e1cfa675-fd30-49d8-8ebe-5516fbbac4da |
| 12/31/2021 | 1/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products (Updated January 7, 2022) | The intent of this document is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 01/01/2022, unless otherwise noted. | 0.1 | | 1/01/2022 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products (Updated January 7, 2022) | 5b4a4df3-2ec7-47ba-b80b-226612429235 |
| 12/31/2021 | Coverage of the COVID-19 Vaccination for Independence Commercial Members (Effective January 1, 2022) | The purpose of this communication is to provide notice regarding information and procedure codes related to the coverage of SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) vaccines and administration of the vaccines for Independence commercial members.
| 0.1 | | Coverage of the COVID-19 Vaccination for Independence Commercial Members (Effective January 1, 2022) | 3cfe3290-4ddb-4090-9c77-4c3692225792 |
| 12/1/2021 | Expiration of Coverage for Consumer Grade Pulse Oximeters Effective January 1, 2022 for Commercial Members | The purpose of this communication is to provide advance notification of our position on consumer grade pulse oximetry devices for use in the home setting, which will expire January 1, 2022 for Commercial members.
| 0.1 | | Expiration of Coverage for Consumer Grade Pulse Oximeters Effective January 1, 2022 for Commercial Members | a7ba1e36-4191-49bc-bfde-997134a1580e |
| 10/1/2021 | 10/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/1/2021, unless otherwise noted.
For more information related to these services, please refer to specific policies when applicable. | 0.1 | | 10/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | 490ecf35-0761-440c-b534-a035b758d9eb |
| 9/17/2021 | Preventive Coverage of Work-up and Follow-up Services for Pre-exposure Prophylaxis for the Prevention of HIV for Independence Members | The purpose of this communication is to provide notice regarding the preventive coverage of services received by an individual prior to beginning pre-exposure prophylaxis for the prevention of HIV and on-going follow-up and monitoring for Independence members.
| 1 | | Preventive Coverage of Work-up and Follow-up Services for Pre-exposure Prophylaxis for the Prevention of HIV for Independence Members | 7bb86f43-944b-46f0-b5b6-ce37e0d34afb |
| 8/19/2021 | Expanded Coverage of Recombinant zoster vaccine (Shingrix) for Independence Commercial Members |
The purpose of this communication is to provide notice regarding the expanded coverage criteria for recombinant zoster vaccine (Shingrix) for Independence commercial members effective July 26, 2021.
| 0.1 | | Expanded Coverage of Recombinant zoster vaccine (Shingrix) for Independence Commercial Members | 94e4b1cb-b822-46be-becc-3021ad3823f4 |
| 6/15/2021 | Notification of Upcoming Changes to Pharmacologic Nuclear Stress Testing in response to COVID-19 | The purpose of this NewsFlash is to provide
advance notice that medical necessity reviews will resume for new prior authorization requests on or after July 15, 2021 regarding the use of pharmacologic stress testing with nuclear
imaging in lieu of exercise stress testing.
| 0 | | Notification of Upcoming Changes to Pharmacologic Nuclear Stress Testing in response to COVID-19 | 2b76b463-a26c-4b24-b3f3-b98732caee8e |
| 4/20/2021 | Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Commercial Independence Members (Updated December 15, 2021) | The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Commercial Independence members. This communication addressing Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) shall remain in effect through the end of the Public Health Emergency.
Note: Information related to SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) is continuously evolving. The Company is closely monitoring the outbreak caused by the novel coronavirus, and will update our communications accordingly.
This document replaces the version published on March 19, 2021. Language in the section for SPECIMENS COLLECTED BY A MEMBER was revised for clarity.
| 0 | | Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Commercial Independence Members (Updated December 15, 2021) | e608b28d-f17e-4672-a1d3-39e5eed12c77 |
| 4/1/2021 | 4/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 4/1/2021, unless otherwise noted.
| 0.1 | | 4/1/2021 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | c832c919-e231-49f5-b0dc-09bc2f5e33b7 |
| 1/4/2021 | 1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Products | The intent of this document is to communicate Commercial Product coverage determinations for services identified through the Annual Code Update process.
| 0 | | 1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Products | b976b7b6-ff87-4f04-a559-d2f8805e0586 |
| 10/22/2020 | Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Commercial Members (Updated January 11, 2022) | The purpose of this document is to communicate the Company's coverage position for Pharmaceutical Treatment of COVID-19 for Independence Commercial members.
| 0.1 | | Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Commercial Members (Updated January 11, 2022) | 308fee6f-a344-469e-b074-445096deb273 |
| 10/1/2020 | 10/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/1/2020, unless otherwise noted.
For more information related to these services, please refer to specific policies when applicable.
| 1 | | 10/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | c322926f-ec73-4821-aac6-943615dd055a |
| 7/1/2020 | 7/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | | 1 | | 7/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | 5D38243F686BE26685258598006308EB |
| 5/12/2020 | Pharmacologic Nuclear Stress Testing in Response to COVID-19 (Updated June 15, 2021)
| The purpose of this News Article is to provide advance notice regarding the use of pharmacologic stress testing with nuclear imaging in response to the Public Health Emergency (PHE) for the COVID-19 pandemic. | 1 | | Pharmacologic Nuclear Stress Testing in Response to COVID-19 (Updated June 15 2021) | 5A7DE68A793E25EB852585650075011A |
| 4/29/2020 | Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-19 (December 15, 2021)
| The purpose of this News Article is to provide advance notice regarding direct supervision requirements for Incident to services performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in response to Coronavirus Disease 2019 (COVID-19). | 1 | | Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-19 (December 15, 2021) | CC0B8A7BBD74419185258558007CCF61 |
| 4/1/2020 | 4/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products (revised 05/04/2020) | The intent of this news article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 4/1/2020. | 1 | | 4/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products (revised 05/04/2020) | 7826A7FDF85578D38525855E004A1326 |
| 12/27/2019 | 1/1/2020 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Products | The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Annual Code Update process. The procedure codes that represent these services will become effective on 1/1/2020. | 1 | | 1/1/2020 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Products | 878452BEE2294FD4852584DD004BB52E |
| 10/1/2019 | 10/1/2019 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this article is to communicate Commercial Product coverage positions for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/1/2019. | 1 | | 10/1/2019 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | 321EEF85779238BD85258486004A8212 |
| 8/8/2019 | Clinical Appropriateness Guidelines for Radiology to be updated for Independence Commercial Members | The purpose of this news article is to provide advance notice regarding upcoming AIM Clinical Appropriateness Guidelines for Radiology for Independence Commercial Members. | 1 | | Clinical Appropriateness Guidelines for Radiology to be updated for Independence Commercial Members | AE4CC970FD87BFDD852584500072AB0F |
| 7/1/2019 | 7/1/2019 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | The intent of this article is to communicate Commercial Product coverage positions for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 7/1/2019. | 1 | | 7/1/2019 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | 5F5B3FF86094E6EF8525842A006CBA5C |
| 5/14/2018 | Meniscal allograft transplantation performed in combination with treatment of focal articular cartilage lesions | The purpose of this communication is to provide notice regarding coverage position of meniscal allograft transplantation performed in combination with treatment of focal articular cartilage lesions. | 1 | | Meniscal allograft transplantation performed in combination with treatment of focal articular cartilage lesions | D1785854FDED826B8525828D00670D5E |
| 5/14/2018 | Minimally invasive fusion/stabilization of the sacroiliac joint using a titanium triangular implant
| The purpose of this communication is to provide notice regarding updated coverage position for minimally invasive fusion/stabilization of the sacroiliac joint using a titanium triangular implant | 1 | | Minimally invasive fusion/stabilization of the sacroiliac joint using a titanium triangular implant | F3BC3AC3678CB7708525828D006A66E3 |
